Skip to main content
Evidence Snapshot

Beta-1 adrenergic receptor

CHEMBL3252 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3252
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-1 adrenergic receptor as ChEMBL target CHEMBL3252, mapped to UniProt P18090. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-1 adrenergic receptor
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL3252
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P18090
Beta-1 adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Beta-1 adrenergic receptor matters

As of 2026-09-13

Beta-1 adrenergic receptor is reviewed as Beta-1 adrenergic receptor (UniProt P18090); the current evidence base includes 19 approved drugs, 378 compounds, and 80 assays, with lead potency reaching pChEMBL 10.4.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 19 approved drugs, 378 compounds, and 80 assays for this target. The dominant activity type is KI. CHEMBL378501 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL378501 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
19 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Beta-1 adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P18090, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

378
Total Compounds
80
Total Assays
19
Approved Drugs
IC50: 23.0, KI: 229.0, EC50: 12.0, KD: 55.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL378501
10.4 Ki
No preferred name
CHEMBL210309
10.2 Kd
No preferred name
CHEMBL543955
9.6 Kd
No preferred name
CHEMBL267375
9.3 Kd
9.1 Ki Approved

Approved Drugs

Structure Compound First Approval
LEVOBETAXOLOL
CHEMBL1201274
2000
CARVEDILOL
CHEMBL723
1995
1985
BETAXOLOL
CHEMBL423
1985
TIMOLOL
CHEMBL499
1978
METOPROLOL
CHEMBL13
1978
PROPRANOLOL
CHEMBL27
1967
ISOPROTERENOL
CHEMBL434
1956
NOREPINEPHRINE
CHEMBL1437
1950
PRACTOLOL
CHEMBL6995
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3252